Results

eNauka >  Rezultati >  Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Naziv: Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
Autori: Coles, Alasdair J; Twyman, Cary L; Arnold, Douglas L; Cohen, Jeffrey A; Confavreux, Christian; Fox, Edward J; Hartung, Hans-Peter; Havrdova, Eva; Selmaj, Krzysztof W; Weiner, Howard L;
Miller, Tamara; Fisher, Elizabeth; Sandbrink, Rupert; Lake, Stephen L; Margolin, David H; Oyuela, Pedro; Panzara, Michael A; Compston, D Alastair S;
Godina: 2012
Publikacija: The Lancet
ISSN: 0140-6736 Lancet Pretraži identifikator
Tip rezultata: Naučni članak
Kolacija: vol. 380 br. 9856 str. 1829-1839
DOI: 10.1016/s0140-6736(12)61768-1
WoS-ID: 000311435000028
Scopus-ID: 2-s2.0-84869507357
URI: https://enauka.gov.rs/handle/123456789/307861
Izvor metapodataka: Migrirano iz RIS podataka
M-kategorija: 
21a+M21a+ - Vodeći međunarodni časopis kategorije M21a+

1,071
SCOPUSTM
822
OpenCitations
949
WEB OF SCIENCETM
Altmetric
Dimensions
Unpaywall

Items in eNauka are protected by copyright, with all rights reserved, unless otherwise indicated.